Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, Japan

Abstract

AbstractAimAlthough hepatitis delta virus (HDV) coinfection with hepatitis B virus (HBV) is a global health concern, the global prevalence of HDV infections remains unknown due to insufficient data in many countries. In Japan, HDV prevalence has not been updated for over 20 years. We aimed to investigate the recent prevalence of HDV infections in Japan.MethodsWe screened 1264 consecutive patients with HBV infection at Hokkaido University Hospital between 2006 and 2022. Patients' serums were preserved and subsequently tested for HDV antibody (immunoglobulin‐G). Available clinical information was collected and analyzed. We compared the changes in liver fibrosis using the Fibrosis‐4 (FIB‐4) index between propensity‐matched patients with and without the evidence of anti‐HDV antibodies and corrected for baseline FIB‐4 index, nucleoside/nucleotide analog treatment, alcohol intake, sex, HIV coinfection, liver cirrhosis, and age.ResultsAfter excluding patients without properly stored serums and those lacking appropriate clinical information, 601 patients with HBV were included. Of these, 1.7% of patients had detectable anti‐HDV antibodies. Patients with anti‐HDV antibody serum positivity had a significantly higher prevalence of liver cirrhosis, significantly lower prothrombin time, and a higher prevalence of HIV coinfection than those who demonstrated serum anti‐HDV antibody negativity. A propensity‐matched longitudinal analysis revealed that liver fibrosis (FIB‐4 index) progressed more rapidly in patients with positive results for anti‐HDV antibody tests.ConclusionsThe recent prevalence of HDV infections in Japanese patients with HBV was 1.7% (10/601). These patients experienced rapid liver fibrosis progression, highlighting the importance of routine HDV testing.